Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H18ClNO2 |
Molecular Weight | 255.741 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1NC(C)(C)CO[C@@]1(O)C2=CC=CC(Cl)=C2
InChI
InChIKey=RCOBKSKAZMVBHT-TVQRCGJNSA-N
InChI=1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-,13+/m0/s1
Radafaxine (GW353162, ( )-(2S,3S)-2-(3-chlorophenyl-3,5,5-trimethyl-2-morphinol) or S,S-hydroxybupropion) is an active metabolite of bupropion. It acts as an inhibitor of the dopamine transporter. Radafaxine was investigated for the treatment of depression however, development was discontinued.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, ADULT n = 365 Health Status: unhealthy Condition: major depressive disorder Age Group: ADULT Sex: unknown Food Status: UNKNOWN Population Size: 365 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00057213
Once-daily oral radafaxine (GW353162) (20-40-60mg) was investigated over an eight-week treatment period in phase 2 study in subjects with major depressive disorder
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000088382
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
C81083
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
8511
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
SUB23070
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
DTXSID501318447
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1172928
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
Q47741214K
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
DB11790
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
RADAFAXINE
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
C496215
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
192374-14-4
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY | |||
|
9795056
Created by
admin on Fri Dec 15 16:01:05 GMT 2023 , Edited by admin on Fri Dec 15 16:01:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)